原創生醫 (6483.TW) 2025Q2 financial report shows operating expenses of 21.6M TWD, much higher than last year, indicating the company is aggressively expanding or strengthening its business layout, possibly investing in marketing, R&D, or talent. It is recommended to also monitor expense control, revenue growth, and cash flow performance, and compare with peers. Integrating diversified data and Growin AI Value Analysis helps confirm whether these investments have good return potential. If the company can continue efficient resource utilization and drive positive business results, it will help strengthen medium- and long-term value.